Resistance to paclitaxel, a first line therapy in the treatment for ovarian cancer, was reversed with HDAC6 inhibition [26,27] in which combination treatment of HDAC6i and Paclitaxel resulted in the synergistic killing of resistant ovarian cancer cells in vitro [28] and in vivo [29]. Here, HDAC6 is linked to ovarian carcinoma.